A Comparative Study of Tolerability of Losartan versus Atenolol in Essential Hypertension and Their Effect on Lipid Profile
Abstract
Hypertension is a vascular disease entity that is a common problem occurring worldwide, characterized by sustained elevated blood pressure. Losartan and atenolol are two medications that are commonly used in hypertensive patients. However, the mechanism of tolerability their effect on lipid profile is not clearly described. Thus, the aims of this study were to study the tolerability of losartan with atenolol in patients with hypertension and the changes in lipid profile on treatment. This research was a prospective, open-label, parallel-group, comparative study conducted in the medicine out-patient department (OPD), where 100 patients aged 40-60 years with newly diagnosed mild and moderate hypertension. We classified patients randomly into two groups, losartan, and atenolol (50 patients of each). Patients were recruited for a period of 6 months and were called for follow-up visits at the third and sixth months. In this study mean age of the patients was 52.72 years. Our study observed that baseline systolic (P=0.704), as well as diastolic blood pressure (BP) (P=0.324), was comparable between both groups. Both systolic (P=0.125), as well as diastolic BP (P=0.108) at 6-months, was comparable between both groups. It was observed that mean total cholesterol levels were comparable between both groups at baseline (P=0.665). Moreover, adverse effects were observed more commonly in group atenolol, headache being the most common followed by dizziness and palpitation. Our study observed that both losartan and atenolol are equally effective in long- term reduction of blood pressure. Additionally, losartan also significantly improved lipid profile.
Keywords
Full Text:
PDFReferences
Theodare A. Hypertensive vascular disease. Longo DL, Kasper DL, Fauci AS, Hauer SL,J ameson JL and Locscalzo J. Harrison’s Principles of Internal Medicine.19thED.New York: Macgraw Hill;2015;P.1611-1627.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK and He J. Global burden of hypertension : analysis of world wide data. Lancet. 2005 jan15;365(9455):217-23.
Satoskar RS et.al. pharmacology and pharmacotherapeutics. 25th edition;2017:426-53
Walker R, Whittlesea C. Clinical Pharmacy and Therapeutics. Fifth edition, Churchill Livingstone-Elsevier, London, United Kingdom. 2012.
Walker BR, Colledge NR, Ralston SH, Penman ID. Davidson’s Principles and Practice of Medicine. Twenty second edition, Churchill Livingstone-Elsevier, Edinburgh, United States of America. 2014.
J. M. Harvey and D. G. Beevers, Biochemical investigation of hypertension. Annals of Clinical Biochemistry. 1990:274-287–296.
C. Borghi, Interactions between hypercholesterolemia and hypertension: implications for therapy. Current Opinion in Nephrology and Hypertension. 2002:11(5):489–496.
J. D. Neaton and D. Wentworth. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316 099 white men. Archives of Internal Medicine. 1992:152(1):56–64,
Chandra SK, Ramesh G. The fourth-generation Calcium channel blocker: Cilnidipine. Indian Heart Journal. 2013 Dec 31;65(6):691-5.
Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs. 1996 May;51(5):820-45. doi: 10.2165/00003495-199651050-00008. Erratum in: Drugs 1996 Oct;52(4):540. PMID: 8861549.
Dahlof B, Devereaux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1003.
Wadworth AN, Murdoch D, Brogden RN. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 1991:Sep;42(3):468-510.
Lawes CM,Vander Hoorn S,Rodgers A. Global burden of blood-pressure-related disease,2001. Lancet. 2008:371(9623): 1513-1518.
Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New England Journal Medicine. 2003:348(7): 583-592.
Dahlof B, Devereaux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1003.
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, BeeversG, deFaire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002:359(9311):995-1003.
Hanefeld M and Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. Journal of Internal Medicine Research. 2001:29:270-9.
Ganesh Dakhale, Anoop Salve, Mrunalini Hardas, Mohini Mahatme, Sachin Hiware and Abhijit Shinde, Clinical efficacy and safety of telmisartan versus losartan and their effect on lipid profile in stage 1 hypertension: A randomized, double blind, 12 week trial. International Journal of Pharmacological Research. 2015:5(4)
Neaton JD et al. Treatment of mild hypertension study (TOMHS)-Final results. JAMA. 1993; 270: 713–724
Kasper D, Fauci A. Harrison’s principles of internal medicine. 19th edition. New York: McGraw-Hill Education; 2015. P.1612
Inoue T., Taguchi I, Abe S et al. Inhibition of intestinal cholesterol absorption might explain cholesterol lowering effect of telmisartan. Journal of Clinical Pharmacutical Therapy. 2011:36(1): 103-110.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension. 1985;7:105–112
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108(6):684-90
Everett AD, Tufro-McReddie A, Fisher A, et al. Angiotensin inhibitors regressed cardiac hypertrophy and transforming growth factor-1 expression. Hypertension. 1994;23:587–592.
Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. American Journal of Hypertension. 1998;11:1394–1404.
Olsen MH, Wachtell K, Beevers G, Dahlöf B, de Simone G, Devereux RB, et al. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Journal of Hypertension. 2009 Mar;27(3):567-74
DOI: https://doi.org/10.15416/pcpr.v6i3.32831
Refbacks
- There are currently no refbacks.
